• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

布伦加特术前分期系统在肝门部胆管癌中的应用:380 例患者的可切除性和预后分析。

The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients.

机构信息

Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

出版信息

J Am Coll Surg. 2012 Sep;215(3):343-55. doi: 10.1016/j.jamcollsurg.2012.05.025. Epub 2012 Jun 28.

DOI:10.1016/j.jamcollsurg.2012.05.025
PMID:22749003
Abstract

BACKGROUND

Complete resection of hilar cholangiocarcinoma (HCCA) is a critical determinant of long-term survival. This study validates a previously reported preoperative clinical T staging system for determining resectability of HCCA.

STUDY DESIGN

Consecutive patients with confirmed HCCA treated over an 18-year period were included. Patient demographics, preoperative imaging studies, resection type, margin status, lymph node status, histopathologic findings, morbidity, and outcomes were entered prospectively and analyzed retrospectively; changes in these variables over time were assessed. All patients were placed into 1 of 3 stages based on the extent of ductal involvement by tumor, portal vein compromise, or lobar atrophy.

RESULTS

From March 1991 through December 2008, 380 patients were evaluated. Eighty-five patients had unresectable disease; 295 patients underwent exploration with curative intent. One hundred fifty-seven patients underwent resection: 129 (82.2%) had a concomitant hepatic resection and 120 (76.4%) had an R0 resection. Of the 32 actual 5-year survivors (120 at risk), 30 patients (93.8%) had a concomitant hepatic resection. In patients who underwent an R0 resection, concomitant partial hepatectomy, well-differentiated histology, and negative lymph nodes were independent predictors of long-term survival. In the 376 patients whose disease could be staged, the preoperative clinical T staging system predicted resectability (p < 0.001), metastatic disease (p < 0.001), and R0 resection (p = 0.007).

CONCLUSIONS

The preoperative clinical T staging system of Blumgart, defined by the radial and longitudinal tumor extent, accurately predicts resectability of HCCA. The full outcomes benefit of resection is realized only if a concomitant partial hepatectomy is performed.

摘要

背景

肝门部胆管癌(HCCA)的完全切除是长期生存的关键决定因素。本研究验证了先前报道的用于确定 HCCA 可切除性的术前临床 T 分期系统。

研究设计

纳入了在 18 年期间接受过确诊的 HCCA 治疗的连续患者。前瞻性地输入了患者的人口统计学数据、术前影像学研究、切除类型、切缘状态、淋巴结状态、组织病理学发现、发病率和结果,并进行回顾性分析;评估了这些变量随时间的变化。所有患者根据肿瘤累及胆管的范围、门静脉侵犯或肝叶萎缩程度,被分为 3 个阶段之一。

结果

1991 年 3 月至 2008 年 12 月,共评估了 380 名患者。85 名患者患有不可切除的疾病;295 名患者接受了以治愈为目的的探查。157 名患者接受了切除:129 名(82.2%)进行了联合肝切除术,120 名(76.4%)进行了 R0 切除。在 32 名实际的 5 年幸存者(120 名有风险)中,30 名患者(93.8%)进行了联合肝切除术。在接受 R0 切除的患者中,联合部分肝切除术、分化良好的组织学和阴性淋巴结是长期生存的独立预测因素。在可分期的 376 名患者中,术前临床 T 分期系统预测了可切除性(p < 0.001)、转移性疾病(p < 0.001)和 R0 切除(p = 0.007)。

结论

Blumgart 的术前临床 T 分期系统,通过肿瘤的径向和纵向范围来定义,准确预测了 HCCA 的可切除性。只有进行联合部分肝切除术,才能实现切除的全部获益。

相似文献

1
The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients.布伦加特术前分期系统在肝门部胆管癌中的应用:380 例患者的可切除性和预后分析。
J Am Coll Surg. 2012 Sep;215(3):343-55. doi: 10.1016/j.jamcollsurg.2012.05.025. Epub 2012 Jun 28.
2
Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.225例肝门部胆管癌患者的分期、可切除性及预后
Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9. doi: 10.1097/00000658-200110000-00010.
3
Hilar cholangiocarcinoma: the Memorial Sloan-Kettering Cancer Center experience.肝门部胆管癌:纪念斯隆-凯特琳癌症中心的经验。
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):490-6. doi: 10.1007/s00534-009-0205-4. Epub 2009 Oct 6.
4
The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases.门静脉切除对肝门部胆管癌预后的影响:305 例多机构分析。
Cancer. 2012 Oct 1;118(19):4737-47. doi: 10.1002/cncr.27492. Epub 2012 Mar 13.
5
Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience.新时代肝门部胆管癌的外科治疗: 来自首尔峨山医院的经验。
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):476-89. doi: 10.1007/s00534-009-0204-5. Epub 2009 Oct 23.
6
Preoperative evaluation with T-staging system for hilar cholangiocarcinoma.采用T分期系统对肝门部胆管癌进行术前评估。
World J Gastroenterol. 2007 Nov 21;13(43):5754-9. doi: 10.3748/wjg.v13.i43.5754.
7
Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence.肝门部胆管癌切除术:同期肝切除可降低肝内复发率。
Ann Surg. 2008 Aug;248(2):273-9. doi: 10.1097/SLA.0b013e31817f2bfd.
8
Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients.肝门部胆管癌的扩大肝切除术:46例患者分析
Arch Surg. 2004 May;139(5):514-23; discussion 523-5. doi: 10.1001/archsurg.139.5.514.
9
Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system.肝门部胆管癌:扩散模式、肝切除在根治性手术中的重要性及术前临床分期系统
Ann Surg. 1998 Sep;228(3):385-94. doi: 10.1097/00000658-199809000-00011.
10
Significance of ductal margin status in patients undergoing surgical resection for extrahepatic cholangiocarcinoma.肝外胆管癌手术切除患者胆管切缘状态的意义
World J Surg. 2007 Sep;31(9):1788-1796. doi: 10.1007/s00268-007-9102-7. Epub 2007 Jul 25.

引用本文的文献

1
Comparison of prognostic factors and their differences in intrahepatic, hilar, and distal cholangiocarcinoma: A systematic review and meta-analysis.肝内、肝门部和肝外胆管癌预后因素及其差异的比较:一项系统评价和荟萃分析。
World J Gastrointest Oncol. 2025 Jul 15;17(7):107995. doi: 10.4251/wjgo.v17.i7.107995.
2
Perihilar cholangiocarcinoma: a surgeon's perspective.肝门部胆管癌:外科医生的视角
ILIVER. 2022 Apr 5;1(1):12-24. doi: 10.1016/j.iliver.2022.03.004. eCollection 2022 Mar.
3
Extrahepatic Intraductal Papillary Neoplasms of Bile Duct and Klatskin Tumor: Simultaneous Occurrence and Recurrence?
胆管肝外导管内乳头状肿瘤与肝门部胆管癌:同时发生与复发?
ACG Case Rep J. 2024 Sep 27;11(10):e01522. doi: 10.14309/crj.0000000000001522. eCollection 2024 Oct.
4
Endoscopic treatment of unresectable perihilar cholangiocarcinoma: beyond biliary drainage.不可切除性肝门部胆管癌的内镜治疗:超越胆道引流
Therap Adv Gastroenterol. 2025 Apr 14;18:17562848251328595. doi: 10.1177/17562848251328595. eCollection 2025.
5
Safety and efficacy of living donor liver transplantation for unresectable perihilar cholangiocarcinoma: A single center prospective study.活体供肝肝移植治疗不可切除肝门部胆管癌的安全性和有效性:一项单中心前瞻性研究。
J Hepatobiliary Pancreat Sci. 2025 Apr;32(4):276-286. doi: 10.1002/jhbp.12121. Epub 2025 Feb 25.
6
Treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis: a comprehensive review.原发性硬化性胆管炎患者胆管癌的治疗:综述
eGastroenterology. 2024 Mar 29;2(1):e100045. doi: 10.1136/egastro-2023-100045. eCollection 2024 Jan.
7
Cholangiocarcinoma in Latin America: a multicentre observational study alerts on ethnic disparities in tumour presentation and outcomes.拉丁美洲的胆管癌:一项多中心观察性研究对肿瘤表现和预后方面的种族差异发出警示。
Lancet Reg Health Am. 2024 Nov 25;40:100952. doi: 10.1016/j.lana.2024.100952. eCollection 2024 Dec.
8
Hybrid FDG-PET/MRI for Diagnosis and Clinical Management of Patients with Suspected Perihilar Cholangiocarcinoma: A Feasibility Pilot Study.用于疑似肝门部胆管癌患者诊断及临床管理的混合正电子发射断层显像-磁共振成像(FDG-PET/MRI):一项可行性初步研究
Nucl Med Mol Imaging. 2024 Oct;58(6):364-376. doi: 10.1007/s13139-024-00873-2. Epub 2024 Aug 1.
9
Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and Outcome.肝外胆管癌:与解剖位置和预后相关的基因组变量。
JCO Precis Oncol. 2024 Jul;8:e2400206. doi: 10.1200/PO.24.00206.
10
Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma.胆管癌定向分子疗法的当前及未来治疗靶点
Cancers (Basel). 2024 Apr 26;16(9):1690. doi: 10.3390/cancers16091690.